Background: The purpose of this study was to quantify the relationship among age, pretreatment comorbidity, and survival outcomes in patients with locally advanced laryngeal cancer.
Methods: Baseline comorbidity data were collected and age-adjusted Charlson Comorbidity Index (CCI) was calculated for each case. Kaplan-Meier and Cox proportional hazards modeling were used to determine associations with survival.
Results: For 548 patients, with a median age of 59 years (range 31-91 years), 58% were treated with larynx preservation and the rest with total laryngectomy and adjuvant radiotherapy (RT). Two hundred thirty-eight patients (43%) had at least 1 comorbidity each. Cardiovascular diseases were the most common comorbidities (19%). The 5-year overall survival (OS) for patients with CCI 3 (n 5 442) were superior to CCI >3 (n 5 106; 60% vs 41%; P < .0001), although the 5-year diseasespecific survival (DSS) rates were not significantly different. The 5-year noncancer CSS was better for age-adjusted CCI 3 (88% vs 67%; P < .0001).
Conclusion:
The age-adjusted CCI is a significant predictor of noncancer CSS and OS for patients with locally advanced laryngeal cancer but is not associated with DSS.
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| I NT ROD UCTI ON
Preexisting medical comorbidities present additional challenges for older patients with head and neck cancer, in which a significant proportion of patients have also been users of tobacco and alcohol. These patients are at a greater risk for cardiovascular and respiratory illnesses in addition to the development of squamous cell carcinoma (SCC) in the aerodigestive tract. [1] [2] [3] [4] [5] [6] Up to 65% of patients with head and neck cancer are afflicted with clinically relevant pretreatment comorbidities. 3, 5, 7, 8 Although there have been many advances in surgical larynx preservation strategies, advances in chemotherapy (CRT) and radiotherapy (RT) have led to a shift from surgery to laryngeal preservation therapy in the treatment of advanced laryngeal carcinomas. 9, 10 Patients treated for laryngeal SCC may enjoy better survival outcomes, as compared to other tobacco-driven (eg, oral cavity cancers), making them more susceptible to competing causes of death from comorbidities and other factors. [1] [2] [3] 5, 11 Comorbidities have been shown to play a significant role in many aspects of care in elderly patients with cancer, including treatment selection, response to therapy, tumor progression, morbidity, and survival outcomes. Multiple studies have demonstrated that pretreatment comorbidity status is an independent predictor of overall survival (OS). [1] [2] [3] [4] [5] [6] [7] [8] [9] [11] [12] [13] Selective studies have elaborated on the timing of competing mortalities, establishing a specific time point in which head and neck cancer mortality risk is overtaken by the risk of noncancer-cause mortality. 1, 2, 11, 12, 14 However, to our knowledge, no study has described this time point in patients with locally advanced laryngeal SCC. To this end, the primary purpose of this study is to characterize the association between age and/or pretreatment comorbidity with survival outcomes for patients with locally advanced laryngeal SCC. 13, 15 Furthermore, we aim to explore the effect of age and/or comorbidities per each treatment strategy, as well as establish a specific time point in which laryngeal cancer mortality risk is exceeded by the risk of noncancer-cause mortality. death was manually coded with patients having active cancer at the time of death were coded as a "cancer-related death," and patients without active disease at last follow-up were coded as a "noncancer-related death."
| MA TERI A LS AND M ETH ODS

| Patients
| Comorbidity assessment
The Charlson Comorbidity Index (CCI) was used to obtain and evaluate comorbidity data from our patient population. The CCI was originally developed in 1987 to characterize and quantify the prognostic effect of comorbidities in patients with breast cancer. The scores were created with regard to their weighted overall mortality risk. 16 The CCI has since been validated in the head and neck cancer population by Singh et al 17 who described its utility and ease of use in the setting of retrospective studies. In addition, the ageadjusted CCI was calculated by adding 1 point to the CCI score for every decade over the 40s. 18 Age-adjusted CCI has recently been validated in the nasopharyngeal carcinoma patient population. 19 
| Survival end points
The Kaplan-Meier product limit method was used to calculate (from the date of diagnosis) 5-year and 10-year overall survival, disease-specific survival (DSS; defined as death from laryngeal cancer coded as an event, with all others censored), noncancer cause-specific survival (CSS; in which all deaths recorded in patients without active cancer at the time of last follow-up were coded as events, with all others censored). Noncancer CSS was used as a crude estimator of noncancer mortality events. These variables were calculated for the total number of patients as well as patients in each treatment cohort: surgery (total or partial laryngectomy) plus adjuvant therapy (postoperative radiotherapy [PORT]), larynx preservation therapy with induction and/or concurrent CRT, larynx preservation therapy with definitive RT alone.
| Statistical analysis
Competing risk of death was implemented using Weibull parametric fitting using cause of death as a competing risk variable for uncensored data. Initial univariable Cox proportional hazard analysis was used to determine the correlation of the following variables with survival outcomes: age, CCI score, age-adjusted CCI score, ECOG performance status, sex, T classification (T3 vs T4), N classification (N0 vs N1), tumor subsite (glottic vs supra/subglottic), treatment cohort (surgery vs laryngeal preservation [including both larynx preservation plus chemoradiation and larynx preservation plus radiation alone groups]), and chemotherapy (any chemotherapy vs no chemotherapy). Continuous variables that demonstrated a significant association with an outcome in initial analysis were then subjected to recursive partitioning analysis to identify appropriate cutoff thresholds and subsequently converted to binary levels based on the resultant thresholds. The converted binary variables as well as nominal variables with a P value < .1 were included in a multivariable Cox proportional hazard model. For comparison of model performance when adding age, CCI, or age-adjusted CCI to the base model without age or comorbidity information, we used the Bayesian information criterion (BIC). A lower BIC indicates improved model performance and parsimony, using the BIC evidence grades presented by Raftery 20 with the posterior probability of superiority of a lower BIC model based on the difference of tested model and the base model. Per Raftery, 20 a BIC difference of <2 is considered "weak," 2 to 6 denoted "positive," 6 to 10 as "strong," and >10 as "very strong." Survival distributions between various groups were compared with the log-rank test. Data were analyzed using JMP version 11.2 Pro statistical software (SAS Institute, Cary, NC), and statistical significance was determined using a specified non-Bonferroni corrected a of 0.05.
| RES U LTS
| Patient and treatment characteristics
A total of 633 patients with previously untreated T3 or T4 SCC of the larynx presented to our institution during the defined study period. Of these, 85 patients were excluded due to unspecified comorbidity data, leaving 548 patients for analysis. The median follow-up for living patients was 77 months (interquartile range 47-143). The median age at diagnosis was 59 years (interquartile range 52-66 years), and 406 patients (74%) were men. The vast majority (95%) were smokers. Of the 318 patients (58%) who were treated using the laryngeal preservation approach, 206 (65%) received induction (n 5 52), concurrent (n 5 113), or both induction and concurrent (n 5 41) chemotherapy. Of the 230 patients (42%) who underwent total laryngectomy-PORT, 191 (83%) received RT alone followed by total laryngectomy, and 39 (17%) received induction (n 5 7), concurrent (n 5 28), or both induction and concurrent (n 5 4) chemotherapy. Of the entire study population, 104 patients (19%) received induction chemotherapy (induction only n 5 59, induction plus concurrent n 5 45). Of these patients, 55% received platinum plus taxane-based regimens (n 5 57) and 40% received platinum-based regimens (n 5 42). Patient and disease characteristics and treatment characteristics are summarized in Table 1 . At last follow-up, 144 patients (26%) were alive, 176 (32%) had documented cancer-related deaths, 168 (31%) died with no evidence of cancer, 16 (3%) died of second primary cancer, 17 (3%) died of unknown cause, and 27 (5%) were lost to follow-up.
| Comorbidity characteristics
A total of 238 patients (43%) had at least 1 comorbid condition before the start of therapy. The most common types of comorbidities recorded were cardiovascular, which affected 19% of the population (n 5 102), and respiratory, which affected 18% of the population (n 5 98). When stratified by treatment strategy, higher proportion of patients in the larynx preservation-RT group had pretreatment comorbidities (ie, CCI score 1) when compared with both the larynx preservation-CRT group (56% vs 39%; P 5 .004) and the total laryngectomy-PORT group (56% vs 41%; P 5 .007). A detailed summary of patient comorbidity characteristics can be found in Table 2 .
| Age, comorbidity, and survival
Univariable analysis of OS demonstrated that older age (P < .0001), higher CCI score (P 5 .01), higher age-adjusted CCI score (P < .0001), higher ECOG performance status (P 5 .001), supra/transglottic subsites (P 5 .001), and nodalpositive disease (P < .0001) were all associated with worse OS. The recursive partitioning analysis-driven cutoff points associated with worse OS were identified for age 64 years, CCI score >1, age-adjusted CCI score >3, and ECOG performance status >1. A baseline initial multivariable model that included disease subsite, ECOG performance status, N classification, and treatment variables revealed disease subsite, ECOG performance status, and N classification variables were independent correlates of OS with model BIC of 4070, as shown in Table 3 . The addition of either age or ageadjusted CCI to the baseline model achieved equal improvement of model performance with BIC reduction >10 in both, whereas the addition of non-age-adjusted CCI score achieved positive but less substantial reduction of BIC (Table 3) . Univariable analysis of noncancer CSS showed age 64 years (hazard ratio [HR] 2.2; 95% confidence interval [CI] 1.6-3.1; P < .0001), CCI score >1 (HR 1.9; 95% CI 1.3-2.7; P 5 .0009), age-adjusted CCI score >3 (HR 3.0; 95% CI 2.0-4.2; P < .0001), and ECOG performance status >1 (HR 2.7; 95% CI 1.6-4.4; P 5 .0004) were significantly associated with worse noncancer CSS. In multivariable analysis, the addition of age-adjusted CCI achieved the lowest BIC when combined with ECOG performance status and treatment variables with >10 BIC reduction compared with the next best model that included age instead of age-adjusted CCI.
Univariable analysis of DSS showed supra/transglottic subsites (HR 1.5; 95% CI 1.01-2.4; P 5 .04), T4 (HR 1.5; 95% CI 1.1-2.0; P 5 .01), nodal-positive disease (HR 2.4; 95% CI 1.8-3.4; P < .0001), total laryngectomy-PORT (HR 1.6; 95% CI 1.2-2.1; P 5 .003), and no chemotherapy (HR 1.4; 95% CI 1.0-1.8; P 5 .04) were significantly associated with worse DSS. In multivariable analysis, nodal-positive disease (HR 2.5; 95% CI 1.8-3.5; P < .0001) was the single independent significant associate of worse DSS. Figure 1 depicts the Kaplan-Meier survival curves for patients with age-adjusted CCI >3 (n 5 106) compared with those with 3 (n 5 442) with 5-year and 10-year OS of 60% and 39% versus 41% and 15%, respectively (log-rank P < .0001). Patients with age-adjusted CCI 3 had better 5-year and 10-year noncancer CSS as well (88% and 67% vs 64% and 25%; P < .0001). However, there was no statistically significant difference between age-adjusted CCI 3 and ageadjusted CCI >3 with regard to DSS at 5 and 10 years (69% and 59% vs 64% and 64%; P 5 .6) as shown in Figure 2 
| Treatment cohorts
In the surgery cohort (total laryngectomy-PORT), 196 patients (85%) had an age-adjusted CCI 3, and 35 patients (15%) had an age-adjusted CCI >3. The 5-year and 10-year OS were better for patients with age-adjusted CCI 3 compared to age-adjusted CCI >3 (55% and 38% vs 42% and 19%; P 5 .04). The 5-year and 10-year noncancer CSS were also better for patients with age-adjusted CCI 3 (88% and 72% vs 62% and 28%; P < .0001). There was no statistical significant difference between age-adjusted CCI 3 and ageadjusted CCI >3 with regard to DSS at 5 and 10 years (63% and 52% vs 68% and 68%; P 5 .7).
In the larynx preservation-CRT cohort, 162 patients (79%) had an age-adjusted CCI 3, and 44 patients (21%) had an age-adjusted CCI >3. The 5-year and 10-year OS were better for patients with age-adjusted CCI 3 compared to age-adjusted CCI >3 (67% and 49% vs 54% and 14%; P 5 .0009). The 5-year and 10-year noncancer CSS were also better for patients with age-adjusted CCI 3 compared to age-adjusted CCI >3 (90% and 72% vs 72% and 21%; P < .0001). There was no statistical significant difference between age-adjusted CCI 3 and age-adjusted CCI >3 with regard to DSS at 5 and 10 years (75% and 68% vs 76% and 76%; P 5 .8).
In the larynx preservation-RT cohort, 84 (75%) patients had an age-adjusted CCI 3, and 28 (25%) had an ageadjusted CCI >3. The 5-year and 10-year OS were better for patients with age-adjusted CCI 3 compared to age-adjusted CCI >3 (58% and 31% vs 23% and 9%; P 5 .0007). The 5-year and 10-year noncancer CSS were also better for patients with age-adjusted CCI 3 compared to age-adjusted CCI >3 (82% and 52% vs 52% and 26%; P 5 .04). The 5-year and 10-year DSS were better for patients with age-adjusted CCI 3 compared to age-adjusted CCI >3 (71% and 60% vs 41% and 41%; P 5 .03). Supplementary Table S1 summarizes all studied survival end points by age-adjusted CCI and treatment cohort.
| Competing risk of death
Competing risk of death analysis showed that the risk of non-cancer death exceeded the risk of cancer-attributed death approximately 2.5 years posttreatment for patients with ageadjusted CCI >3; whereas noncancer risk of demise never exceeded cancer-specific risk during the entire follow-up period for patients with age-adjusted CCI 3, as shown in Figure 3 . The same analysis was implemented for patients by age groups independent of comorbidity status. Patients older than 64 years had a higher cancer-attributed risk of death for 68 month after treatment, whereas patients younger than 64 years had a higher cancer-attributed risk of death for the entire follow-up period.
| DI S CU S S IO N
Patients undergoing treatment for SCC of the larynx that were tobacco-driven cancers often have the additional burden of preexisting medical comorbidities of sequelae of smoking that are compounded by greater exposure, as can be seen in older patients. The current study is the first to suggest that a quantified age-adjusted CCI score of >3 seems to be of unique prognostic importance. In our series of patients with laryngeal SCC, we demonstrate worse OS in patients older than 64 years and equivalently in patients with an ageadjusted CCI score of >3. The same finding held true for patients concerning noncancer CSS but with the age-adjusted CCI score as the strongest driver of noncancer-related mortality compared with age or non-adjusted CCI. However, neither age nor comorbidities were associated with cancerrelated mortality, whereas the nodal classification was the only independent correlate of cancer-related mortality. These findings were consistent throughout the all 3 cohorts: surgery (total laryngectomy-PORT), larynx preservation-CRT, and larynx preservation-RT. These findings demonstrate, not surprisingly, that older patients with more comorbidities who present before the initiation of therapy do worse in terms of OS and death from noncancer causes when compared with their counterparts. Interestingly, in competing risk analysis for OS, we found that patients with an age-adjusted CCI >3 have noncancer mortality risk greater than that of cancer-related death fairly soon after treatment relative to the persistently higher cancerrelated mortality risk in the other cohort with 3. This data confirms that in older patients with multiple comorbidities in the setting of advanced-stage laryngeal SCC, the risk of cancer-related death is major and should be considered in the multidisciplinary treatment decision.
Previous studies reporting pretreatment comorbidity as a correlate of survival in head and neck cancer consistently showed patients with higher comorbidities had worse survival outcomes. [1] [2] [3] 8, 11, 14 The majority of these studies reported the impact of comorbidities in mixed stages and subsites of head and neck cancer. Bahig et al 21 recently
reported a series of 129 patients 70 years with locally advanced head and neck cancers, mainly oropharyngeal in origin. The study showed the CCI 3 was predictive of cancer-related mortality. It also showed, matching with our findings, that this group of patients have a greater noncancerrelated mortality after 3 years from treatment. Few studies, however, reported the impact of age and comorbidities on survival of patients with laryngeal cancer. [4] [5] [6] [7] Paleri et al 7 demonstrated that moderate and severe comorbidity have a greater and statistically significant impact on survival than the TNM classifications in a series of 180 patients with laryngeal SCC. In a surgically treated cohort of 231 patients with laryngeal cancer, severe comorbidity was associated with higher mortality, particularly in the early stages. A single study by Sabin et al 6 showed that adding age to the comorbidity index reclassified 18% of the 152 patients included in their study from low-grade to high-grade comorbidity. However, in contrast with our results, incorporating age as an additional comorbid condition did not improve the prognostic ability of the CCI. The current study, however, examined the prognostic impact of age and comorbidities in a uniform cohort of T3 to T4 laryngeal SCC. We demonstrated, matching with data reported in previous studies, that both age and comorbidities are strong prognostic factors in locally advanced laryngeal cancer independent of treatment modality due to the high impact of both factors on noncancer-related competing mortality risk. Our study is not without limitations. This is a retrospective patient chart review spanning 3 decades of patient evaluations and treatments. Due to the nature of the medical record keeping systems, both electronic and paper medical records were reviewed, creating the potential for inconsistent record keeping regarding patients' comorbidity status. For example, electronic medical records tend to be more thorough when describing a patient's symptoms and medical comorbidities, which can affect how a patient's CCI score was calculated. Additionally, the act of assigning patients a CCI score has the potential for error in and of itself. Although the CCI scoring system has specific rules and guidelines, there is some level of subjectivity involved in assigning CCI scores to individual patients based on a retrospective review of a patient's chart, including errors and inconsistencies in medical record keeping. Nevertheless, this is, to the best of our knowledge, the largest curated advanced-stage laryngeal SCC dataset that includes detailed treatment information, patient demographic information, and CCI scores. Our study based on this unique dataset is the largest scale analysis of its kind in the United States.
Furthermore, our findings have demonstrated that a simple clinical tool like the age-adjusted Charlson comorbidity index could be of a significant prognostic impact. Because patients with scores higher than 3 can be old patients with few comorbidities, or they can be relatively younger with multiple comorbidities. Therefore, we recommend the routine calculation of this index in clinics to be considered in multidisciplinary treatment decisions as well as for posttreatment surveillance programs. We also recommend using this tool to stratify patients with locally advanced laryngeal SCC in future clinical trials. We believe that although cancer-related death remains the most imminent threat for patients with locally advanced laryngeal SCC and requires aggressive treatment to reduce its risk, noncancer-related death seems to be a very significant hazard in patients with high ageadjusted CCI scores and requires future strategies to personalize treatment/follow-up plans for these patients in order to improve their OS.
| CON CLU S IO N
In conclusion, our findings clearly demonstrate the impact that age and pretreatment comorbidities can have on survival outcomes in the setting of advanced-stage laryngeal cancer. The age-adjusted CCI is a significant predictor of noncancer CSS and OS but is not associated with DSS. Approximately 2.5 years after treatment, patients with age-adjusted CCI >3 have noncancer mortality risk greater than that of cancerrelated death. We maintain that aggressive treatment approaches are important but must be weighed against competing risks, and that comorbidity status be factored into treatment selection decisions.
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